1. Guangzhou Institute of Cardiovascular Disease, Guangdong Key Laboratory of Vascular Diseases, State Key Laboratory of Respiratory Disease, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510260, China 2. Affiliated Cancer Hospital & institute of Guangzhou Medical University, Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Guangzhou, Guangdong 511436, China *These authors contributed equally to this work.
✉ Corresponding author: Ningning Liu, Guangzhou Institute of Cardiovascular Disease, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510260, China, E-mail: liuningningedu.cn or Hongbiao Huang, Affiliated Cancer Hospital & institute of Guangzhou Medical University, Guangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Guangzhou, Guangdong 511436, China, E-mail: huanghongbiaoedu.cn.More
Citation:
Xia X, He J, Liu B, Shao Z, Xu Q, Hu T, Yu C, Liu X, Liao Y, Liu N, Huang H. Targeting ERα degradation by L-Tetrahydropalmatine provides a novel strategy for breast cancer treatment. Int J Biol Sci 2020; 16(12):2192-2204. doi:10.7150/ijbs.44005. https://www.ijbs.com/v16p2192.htm
The incidence and mortality of breast cancer (BCa) are the highest among female cancers. There are approximate 70% BCa that are classified as estrogen receptor alpha (ERα) positive. Therefore, targeting ERα is the most significantly therapeutic schedule. However, patients with breast cancer develop resistance to ERα or estrogen (E2) antagonists such as fulvestrant and tamoxifen. In the present study, we found that L-Tetrahydropalmatine (L-THP) significantly suppressed cell proliferation in ERα+ BCa cells via inducing cell cycle arrest rather than apoptosis. Additionally, L-THP enhanced the sensitivity of ERα+ BCa cells to tamoxifen and fulvestrant. Mechanically, the application of L-THP promotes ERα degradation through accumulating ubiquitin chains on ERα. Overexpressing ERα abrogates L-THP induced-antiproliferation in ERα+ BCa cells. Collectively, our work indicates that L-THP may represent a potentially novel therapeutic medicine for ERα+ breast cancer patient.
Keywords: breast cancer, L-THP, ERα, proliferation, cell cycle
Citation styles
APA
Xia, X., He, J., Liu, B., Shao, Z., Xu, Q., Hu, T., Yu, C., Liu, X., Liao, Y., Liu, N., Huang, H. (2020). Targeting ERα degradation by L-Tetrahydropalmatine provides a novel strategy for breast cancer treatment. International Journal of Biological Sciences, 16(12), 2192-2204. https://doi.org/10.7150/ijbs.44005.
ACS
Xia, X.; He, J.; Liu, B.; Shao, Z.; Xu, Q.; Hu, T.; Yu, C.; Liu, X.; Liao, Y.; Liu, N.; Huang, H. Targeting ERα degradation by L-Tetrahydropalmatine provides a novel strategy for breast cancer treatment. Int. J. Biol. Sci. 2020, 16 (12), 2192-2204. DOI: 10.7150/ijbs.44005.
NLM
Xia X, He J, Liu B, Shao Z, Xu Q, Hu T, Yu C, Liu X, Liao Y, Liu N, Huang H. Targeting ERα degradation by L-Tetrahydropalmatine provides a novel strategy for breast cancer treatment. Int J Biol Sci 2020; 16(12):2192-2204. doi:10.7150/ijbs.44005. https://www.ijbs.com/v16p2192.htm
CSE
Xia X, He J, Liu B, Shao Z, Xu Q, Hu T, Yu C, Liu X, Liao Y, Liu N, Huang H. 2020. Targeting ERα degradation by L-Tetrahydropalmatine provides a novel strategy for breast cancer treatment. Int J Biol Sci. 16(12):2192-2204.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.